Biodexa Pharmaceuticals Plc (NASDAQ:BDRX – Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 189,600 shares, a growth of 183.8% from the March 31st total of 66,800 shares. Based on an average daily trading volume, of 2,030,000 shares, the short-interest ratio is presently 0.1 days.
Biodexa Pharmaceuticals Stock Performance
Biodexa Pharmaceuticals stock opened at $0.72 on Friday. Biodexa Pharmaceuticals has a 52-week low of $0.67 and a 52-week high of $21.44. The stock’s 50 day moving average price is $1.16 and its two-hundred day moving average price is $2.22.
Analyst Ratings Changes
Separately, LADENBURG THALM/SH SH initiated coverage on Biodexa Pharmaceuticals in a report on Thursday, February 8th. They set a “buy” rating and a $8.00 price target on the stock.
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.
Further Reading
- Five stocks we like better than Biodexa Pharmaceuticals
- The 3 Best Retail Stocks to Shop for in August
- Hasbro’s Management Made All the Right Calls This Quarter
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- What is a Low P/E Ratio and What Does it Tell Investors?
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Biodexa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodexa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
